HRP20191131T1 - Pripravak za zdravlje očiju - Google Patents
Pripravak za zdravlje očiju Download PDFInfo
- Publication number
- HRP20191131T1 HRP20191131T1 HRP20191131TT HRP20191131T HRP20191131T1 HR P20191131 T1 HRP20191131 T1 HR P20191131T1 HR P20191131T T HRP20191131T T HR P20191131TT HR P20191131 T HRP20191131 T HR P20191131T HR P20191131 T1 HRP20191131 T1 HR P20191131T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- vitamin
- use according
- eye
- alone
- Prior art date
Links
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 3
- 229930003268 Vitamin C Natural products 0.000 claims 3
- 229930003427 Vitamin E Natural products 0.000 claims 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 3
- 235000012680 lutein Nutrition 0.000 claims 3
- 239000001656 lutein Substances 0.000 claims 3
- 229960005375 lutein Drugs 0.000 claims 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 3
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 3
- 239000006014 omega-3 oil Substances 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 235000019154 vitamin C Nutrition 0.000 claims 3
- 239000011718 vitamin C Substances 0.000 claims 3
- 235000019165 vitamin E Nutrition 0.000 claims 3
- 229940046009 vitamin E Drugs 0.000 claims 3
- 239000011709 vitamin E Substances 0.000 claims 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 3
- 235000010930 zeaxanthin Nutrition 0.000 claims 3
- 239000001775 zeaxanthin Substances 0.000 claims 3
- 229940043269 zeaxanthin Drugs 0.000 claims 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 235000021466 carotenoid Nutrition 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 2
- 235000021283 resveratrol Nutrition 0.000 claims 2
- 229940016667 resveratrol Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 235000015655 Crocus sativus Nutrition 0.000 claims 1
- 244000124209 Crocus sativus Species 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 238000012261 overproduction Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 235000013974 saffron Nutrition 0.000 claims 1
- 239000004248 saffron Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (14)
1. Oftalmološki nutraceutični pripravak koji sadrži:
- vitamine
- mikroelemente
- karotenoide
- omega-3 masne kiseline i
- resveratrol u količini većoj od 20 mg
te navedeni pripravak ne sadrži šafran.
2. Pripravak prema patentnom zahtjevu 1, naznačen time da sadrži količinu resveratrola koja je jednaka ili veća od 30 mg, poželjno veća od 30 mg, poželjnije jednaka ili veća od 50 mg.
3. Pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da su:
- vitamini, sami ili u kombinaciji, izabrani iz skupine koja sadrži vitamin C i vitamin E;
- mikroelemente, sami ili u kombinaciji, izabrani iz skupine koja sadrži cink i bakar;
- karotenoidi, sami ili u kombinaciji, izabrani iz skupine koja sadrži zeaksantin i lutein;
- omega-3 masne kiseline, same ili u kombinaciji, potječu iz ribljeg ulja i poželjno je da su izabrane iz skupine koja sadrži eikozapentaensku kiselinu (EPA) i dokozaheksaensku kiselinu (DHA).
4. Pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da sadrži:
- vitamin C
- vitamin E
- cink
- bakar
- lutein
- zeaksantin i
- omega-3 masne kiseline iz ribljeg ulja, posebice EPA i DHA.
5. Pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da sadrži:
- 50 mg do 500 mg vitamina C, poželjno 240 mg ili 120 mg;
- 10 mg do 500 mg vitamina E, poželjno 30 mg;
- 5 mg do 100 mg cinka, poželjno 12,5 mg;
- 0,2 mg do 10 mg bakra, poželjno 1 mg;
- 2 mg do 50 mg luteina, poželjno 10 mg;
- 0,5 mg do 10 mg zeaksantina, poželjno 2 mg;
- 100 mg do 1000 mg EPA, poželjno 380 mg ili 172 mg; i
- 100 mg do 1000 mg DHA, poželjno 190 mg ili 366 mg.
6. Pripravak prema bilo kojem od patentnih zahtjeva od 1 do 5, naznačen time da se upotrebljava kao dodatak prehrani u oftamologiji.
7. Pripravak prema bilo kojem od patentnih zahtjeva od 1 do 5, naznačen time da se upotrebljava za liječenje patologije oka koja je povezana s prekomjernom ekspresijom VEGF putanje, poželjno s prekomjernom proizvodnjom VEGFR receptora.
8. Pripravak za njegovu uporabu prema patentnom zahtjevu 7, naznačen time da je patologija oka izabrana iz eksudativne AMD, retinalne venske okluzije, makularnog edema, dijabetičkog makularnog edema, miopije, dijabetičke retinopatije, neovaskularnog glaukoma ili neovaskularizacije rožnice.
9. Pripravak za njegovu uporabu prema patentnom zahtjevu 7 ili 8, naznačen time da se daje pacijentu koji ima simptome navedene patologije samo na jednom oku.
10. Pripravak prema bilo kojem od patentnih zahtjeva od 1 do 5, naznačen time da se upotrebljava za:
- održavanje ili poboljšanje zdravlja očiju; i/ili
- prevenciju bolesti oka; i/ili
- modulaciju ekspresije i/ili aktivnosti VEGFR receptora vidnih stanica.
11. Pripravak za njegovu uporabu prema patentnom zahtjevu 10, naznačen time da se upotrebljava kod zdravog pacijenta, poželjno kod mladog rizičnog pacijenta.
12. Pripravak za njegovu uporabu prema bilo kojem od patentnih zahtjeva od 6 do 11, naznačen time da se pripravak daje oralno.
13. Pripravak za njegovu uporabu prema bilo kojem od patentnih zahtjeva od 6 do 12, naznačen time da se pripravak daje dnevno.
14. Pripravak za njegovu uporabu prema bilo kojem od patentnih zahtjeva od 6 do 13, naznačen time da je pripravak u obliku jedne ili više kapsula, poželjno 2 kapsule.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1552483A FR3034018B1 (fr) | 2015-03-25 | 2015-03-25 | Composition ophtalmique nutraceutique pour la sante oculaire |
| EP16719447.1A EP3273947B1 (fr) | 2015-03-25 | 2016-03-25 | Composition pour la sante oculaire |
| PCT/FR2016/050697 WO2016151269A1 (fr) | 2015-03-25 | 2016-03-25 | Composition pour la sante oculaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191131T1 true HRP20191131T1 (hr) | 2019-09-20 |
Family
ID=53674066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191131TT HRP20191131T1 (hr) | 2015-03-25 | 2019-06-19 | Pripravak za zdravlje očiju |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10881638B2 (hr) |
| EP (1) | EP3273947B1 (hr) |
| CA (1) | CA2979112C (hr) |
| CY (1) | CY1121880T1 (hr) |
| DK (1) | DK3273947T3 (hr) |
| ES (1) | ES2732744T3 (hr) |
| FR (1) | FR3034018B1 (hr) |
| HR (1) | HRP20191131T1 (hr) |
| HU (1) | HUE043899T2 (hr) |
| LT (1) | LT3273947T (hr) |
| MA (1) | MA40815A1 (hr) |
| PL (1) | PL3273947T3 (hr) |
| PT (1) | PT3273947T (hr) |
| RS (1) | RS58971B1 (hr) |
| SI (1) | SI3273947T1 (hr) |
| TN (1) | TN2017000380A1 (hr) |
| TR (1) | TR201910056T4 (hr) |
| WO (1) | WO2016151269A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3034018B1 (fr) | 2015-03-25 | 2017-11-03 | Thea Lab | Composition ophtalmique nutraceutique pour la sante oculaire |
| WO2020127641A1 (fr) | 2018-12-20 | 2020-06-25 | Laboratoires Thea | Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire |
| US11141386B1 (en) | 2018-12-28 | 2021-10-12 | QH Holdings (Oregon), Inc. | Eye health supplement with curcumin |
| US11135179B1 (en) | 2018-12-28 | 2021-10-05 | QH Holdings (Oregon), Inc. | Eye health supplement |
| US11090274B2 (en) * | 2019-03-13 | 2021-08-17 | Stuart Richer Consulting, LLC | Formulation and method for supporting retinal health thereby reducing the risk of age-related macular degeneration (AMD) |
| FR3094209B1 (fr) * | 2019-03-25 | 2021-03-12 | Sophie Hvostoff | Composition de desmodium et de chrome trivalent et utilisation a visee oculaire |
| CN114053407B (zh) * | 2020-09-17 | 2023-08-29 | 极目峰睿(上海)生物科技有限公司 | 一种通过调节眼巩膜脂代谢来抑制近视的应用 |
| EP4218717A1 (en) | 2022-02-01 | 2023-08-02 | Laboratoires THEA | Ophthalmic composition comprising resveratrol for treating dry eye syndrome |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006121421A2 (en) * | 2004-01-14 | 2006-11-16 | Robert Ritch | Methods and formulations for treating glaucoma |
| MX286464B (es) * | 2005-12-20 | 2011-05-10 | Cenestra Llc | Formulaciones de acido graso omega 3. |
| US20080181972A1 (en) * | 2007-01-29 | 2008-07-31 | Valentina Amico | Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health |
| US20090226547A1 (en) * | 2008-03-05 | 2009-09-10 | Gilbard Jeffrey P | Dietary Supplement For Eye Health |
| US20120058088A1 (en) * | 2010-06-28 | 2012-03-08 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Methods Of Use |
| GB201014340D0 (en) * | 2010-08-27 | 2010-10-13 | Piraee Mahmood | Nutritional supplement formulation comprising saffron and resveratrol |
| FR3034018B1 (fr) | 2015-03-25 | 2017-11-03 | Thea Lab | Composition ophtalmique nutraceutique pour la sante oculaire |
-
2015
- 2015-03-25 FR FR1552483A patent/FR3034018B1/fr active Active
-
2016
- 2016-03-25 MA MA40815A patent/MA40815A1/fr unknown
- 2016-03-25 PL PL16719447T patent/PL3273947T3/pl unknown
- 2016-03-25 PT PT16719447T patent/PT3273947T/pt unknown
- 2016-03-25 SI SI201630295T patent/SI3273947T1/sl unknown
- 2016-03-25 US US15/557,103 patent/US10881638B2/en active Active
- 2016-03-25 CA CA2979112A patent/CA2979112C/en active Active
- 2016-03-25 HU HUE16719447A patent/HUE043899T2/hu unknown
- 2016-03-25 ES ES16719447T patent/ES2732744T3/es active Active
- 2016-03-25 LT LTEP16719447.1T patent/LT3273947T/lt unknown
- 2016-03-25 EP EP16719447.1A patent/EP3273947B1/fr active Active
- 2016-03-25 DK DK16719447.1T patent/DK3273947T3/da active
- 2016-03-25 RS RS20190805A patent/RS58971B1/sr unknown
- 2016-03-25 TN TNP/2017/000380A patent/TN2017000380A1/fr unknown
- 2016-03-25 TR TR2019/10056T patent/TR201910056T4/tr unknown
- 2016-03-25 WO PCT/FR2016/050697 patent/WO2016151269A1/fr active Application Filing
-
2019
- 2019-06-19 HR HRP20191131TT patent/HRP20191131T1/hr unknown
- 2019-08-08 CY CY20191100850T patent/CY1121880T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1121880T1 (el) | 2020-10-14 |
| DK3273947T3 (da) | 2019-07-01 |
| LT3273947T (lt) | 2019-07-10 |
| RS58971B1 (sr) | 2019-08-30 |
| PT3273947T (pt) | 2019-07-08 |
| FR3034018B1 (fr) | 2017-11-03 |
| US20180042894A1 (en) | 2018-02-15 |
| CA2979112A1 (en) | 2016-09-29 |
| FR3034018A1 (fr) | 2016-09-30 |
| CA2979112C (en) | 2023-06-13 |
| ES2732744T3 (es) | 2019-11-25 |
| TN2017000380A1 (fr) | 2019-01-16 |
| MA40815A1 (fr) | 2018-07-31 |
| HUE043899T2 (hu) | 2019-09-30 |
| PL3273947T3 (pl) | 2019-11-29 |
| WO2016151269A1 (fr) | 2016-09-29 |
| US10881638B2 (en) | 2021-01-05 |
| SI3273947T1 (sl) | 2019-08-30 |
| EP3273947B1 (fr) | 2019-06-12 |
| EP3273947A1 (fr) | 2018-01-31 |
| TR201910056T4 (tr) | 2019-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191131T1 (hr) | Pripravak za zdravlje očiju | |
| KR101904850B1 (ko) | 마이봄선을 표적화하는 영양 보충물 | |
| HRP20151039T1 (hr) | Upotreba omega masnih kiselina za lijeäśenje bolesti | |
| CN103860625A (zh) | 越橘提取物眼用制剂及其制备方法和用途 | |
| US20160067204A1 (en) | Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders | |
| CN104474018A (zh) | 一种缓解视疲劳的保健软胶囊 | |
| BR112017007428A2 (pt) | composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença | |
| HRP20192256T1 (hr) | Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta | |
| G Lawrenson et al. | Controversies in the use of nutritional supplements in ophthalmology | |
| RU2016129079A (ru) | Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы | |
| CN101612161A (zh) | 一种眼药组合物及其制剂 | |
| HRP20230283T1 (hr) | Nutriceutički oftalmološki pripravak za liječenje patoloških stanja retine koja imaju neovaskularnu komponentu | |
| CN104161260A (zh) | 一种用于缓解视疲劳的组合物及其制备方法 | |
| AU2013101038A4 (en) | A dietary supplement to treat dry eyes | |
| ES2413497B1 (es) | Composición con alto contenido en Omega 3, Omega 6 y Omega 9 | |
| RU2021117515A (ru) | Нутрицевтическая офтальмологическая композиция для лечения патологий сетчатки с неоваскулярным компонентом | |
| CN109222086A (zh) | 一种具有缓解视疲劳功效的组合物及其应用和保健食品 | |
| MX2017016991A (es) | Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos. | |
| Chang | Calcium hydroxylapatite | |
| CN106798343A (zh) | 一种具有视力保护功能的深海鱼低聚肽蛋白粉 | |
| Farrer | Dry eye syndrome in the elderly: family features | |
| Regalado Farreras | Sodium hypochlorite | |
| Stuart Richer | Go beyond fish oil with astaxanthin in krill oil | |
| Gaffuri | Non-arteritic ischaemic optic neuropathy causing complete visual loss in an infant: case report | |
| KILIÇ et al. | A Case of Intraretinal and Preretinal Hemorrhages Thought to Develop due to Garlic Extract |